US EditionImbria secures $57.5m to advance ninerafaxstat through Phase IIb trial
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Imbria secures $57.5m to advance ninerafaxstat through Phase IIb trial
Spearheaded by Deep Track Capital, this funding round saw participation from new investors, including Catalio Capital Management, Cytokinetics, and AN Ventures, alongside contributions from current backers SV Health The post Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage